Chabad and Bayer Launch Initiative for Early Detection of Kidney Damage in Diabetics
Translated & summarized from Arutz Sheva by baba
Chabad's "Lev Chabad" organization and Bayer Israel have launched a unique initiative to detect silent kidney damage in diabetes patients. The program aims to raise awareness and provide access to advanced treatments, including Bayer's "Kerendia" drug. Led by Rabbi Levi Mendelson and Rabbi Lazer Katz, the initiative leverages Chabad's extensive network to reach patients nationwide. Early detection through simple urine tests is emphasized as crucial for preventing severe complications like kidney failure and cardiac events.
The story in 5 lines · by baba
- Chabad's Lev Chabad and Bayer Israel launched an initiative for early kidney damage detection in diabetics.
- The program aims to raise awareness and prevent severe complications of type 2 diabetes.
- Elevated protein in urine is identified as the earliest warning sign of kidney damage.
- The initiative will promote simple urine tests and integrate advanced treatments like Bayer's "Kerendia."
- Lev Chabad's nationwide network will ensure the project reaches patients directly.
An initiative combining Chabad's outreach efforts with pharmaceutical advancements has been launched to detect silent kidney damage in diabetes patients. The program unites the international pharmaceutical company Bayer Israel with leaders from the national health organization of Chabad Youth, "Lev Chabad." The project aims to raise awareness and save lives from complications of type 2 diabetes. The initiative is spearheaded by Rabbi Levi Mendelson, director of Lev Chabad, and Rabbi Lazer Katz, director of medical consultation at the organization, along with Bayer executives.
The new project addresses the danger of chronic kidney disease, a serious and often undetected complication of diabetes that can develop over years. Many patients are unaware of the life-threatening risk they face. The initiative focuses on combating the tendency for patients to monitor only blood sugar levels, neglecting gradual damage to vital organs like the kidneys and heart. Experts highlighted that elevated protein (albumin) levels in urine are the earliest warning sign of kidney damage, yet a significant number of patients maintain these dangerous levels even with standard medical treatment. This puts them at high risk for rapid decline into kidney failure and severe cardiac events.
The new program seeks to break this cycle of neglect by urging the public to undergo simple urine tests for protein detection, a test that can prevent severe consequences. In addition to education and diagnosis, the Chabad initiative will work to make innovative pharmacological solutions accessible to patients. This includes integrating advanced treatments, such as Bayer's drug "Kerendia" (finerenone), into the organization's medical guidance. This medication has been shown to reduce the risk of kidney deterioration and cardiac complications in suitable diabetes patients.
The collaboration between the pharmaceutical giant and Lev Chabad, which utilizes a vast network of volunteers, representatives, and medical consultation centers in hospitals and communities nationwide, ensures the project will reach people directly. The organization's leaders emphasized their goal of making life-saving medical knowledge accessible to every citizen, thereby preventing severe illnesses before it is too late.